Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.52 |
| ▸ | ITGAV | P06756 | 14/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836238 | 0.94 | ITGB3 (0.52) | ITGB3ITGAVITGA2BHTTKMT2A | |
| SCHEMBL2841862 | 0.94 | ITGB3 (0.50) | ITGB3ITGAVITGA2BMAPK1LMNA | |
| SCHEMBL2841446 | 0.92 | ITGB3 (0.66) | ITGB3ITGAVITGA2B | |
| SCHEMBL2837406 | 0.90 | ITGB3 (0.54) | ITGB3ITGAVITGA2BMAPK1LMNA | |
| SCHEMBL2836498 | 0.87 | ITGB3 (0.51) | ITGB3ITGAVITGA2BMAPK1LMNA | |
| SCHEMBL2838727 | 0.85 | ITGB3 (0.65) | ITGB3ITGAVITGA2B | |
| SCHEMBL2833615 | 0.85 | ITGB3 (0.63) | ITGB3ITGAVITGA2B | |
| SCHEMBL2837207 | 0.85 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL2839499 | 0.84 | ITGB3 (0.52) | ITGB3ITGAVITGA2BLMNARAB9A | |
| SCHEMBL2833493 | 0.84 | ITGB3 (0.51) | ITGB3ITGAVITGA2BMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | claimed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | claimed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-6974828-B2 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2005-12-13 | — | — | US | disclosed |
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | disclosed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | disclosed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | ITGB3, HCAR3, ADRB3 | ITGB3 1/4885ITGAV 47/4885ITGA2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.